Orders for NatShield Sanitizer Spike after Outbreak of Coronavirus
KUALA LUMPUR / PERTH, Jan 30, 2020 - (ACN Newswire) - ASX-listed Holista CollTech (ASX:HCT, 'Holista') announced today a strong spike in demand in Malaysia for it all-natural disinfectant spray NatShield™ Sanitizer containing the powerful Path-Away® anti-microbial compound. The increased demand follows the recent outbreak of the deadly coronavirus originating in Wuhan, China.
| NatShield Natural Sanitizer |
Holista confirmed that since mid-January 2020 it had sold all NatShield™ Sanitizer in its inventory. Each bottle of NatShield™ Sanitizer contains 5% of Path-Away®, which is made from natural plant-based substances that have been approved for use by the U.S. Food and Drug of Authority and tested by World Health Organization (WHO) approved laboratories in numerous countries around the world.
Developed by Global Infection Control Consultants LLC (GICC LLC) based in South Carolina, USA, Path-Away® (www.path-away.com) is distributed in Malaysia by Holista as NatShield™ Sanitizer. Holista is the exclusive distributor of Path-Away® for the ASEAN region. ASEAN countries with confirmed cases of the coronavirus include Malaysia, Singapore, Thailand and Cambodia.
Based on requests from seven chains representing over 3,000 pharmacies in Malaysia, Holista has ordered 60,000 bottles of NatShield™ Sanitizer to be air-freighted to Malaysia from the U.S.A. by mid-February.
The novel coronavirus was first reported to WHO on 31 December 2019 and has been under investigation ever since. Countries with confirmed infections include the U.S.A., Canada, France, Australia, Japan, South Korea and Nepal.
The active substance in the spray weakens the cell walls of the virus, causing the infectious organisms to clump together, in the process killing themselves, almost instantly. The potent compound is environmentally safe with very low toxicity and hence is not harmful to humans and pets even if accidentally swallowed. It is free of alcohol and other potentially toxic chemicals.
It is approved for use by Malaysia's Ministry of Health, with special reference to the H1N1 virus - another coronavirus, similar to one in this outbreak which led to more than 70 deaths in 2009. It has also been approved by the Food and Safety Authority of New Zealand, and the New Zealand Environmental Protection Authority (EPA). It is approved by the United States Pharmacopeia (USP) and has undergone successful USP-51 testing as a disinfectant.
"This is not a drug. It acts by sanitising body parts. It had been consistently shown to be effective and safe to users and the environment in the most advanced biosafety laboratories in the world," said Dr Rajen Manicka, the CEO of Holista, headquartered in Kuala Lumpur, Malaysia and listed on the Australian Securities Exchange (ASX).
"NatShield™ Sanitizer was created to treat previously known coronaviruses. It can be used as a precautionary spray in crowded areas including public transport. Three to five sprays are all that is needed to disinfect hands, toilet seats, doorknobs, countertops and trolley bars, with efficacy lasting up to two hours. We plan to sell it in all infected ASEAN countries," he said.
Dr Arthur Martin, the President of GICC LLC (www.giccllc.com) said, "The Path-Away® formula has been proven in world-renowned laboratories including those working with WHO, to be able to kill over 170 deadly pathogens including previously existing forms of coronaviruses. Path-Away® is currently undergoing testing on the newly emerged coronavirus, designated as novel coronavirus 2019-nCoV. Dr Martin, a globally respected scientist and a member of the WHO's Stop Tuberculosis (T.B.) Board, had been previously nominated for the prestigious Kochon Prize for his work on T.B. "Humans of all ages can use Path-Away® with little or no risk of toxic effects. It retains its efficacy for hours even under extremes of temperature and is not corrosive and can be used even in sensitive installations," he said.
Contact: Corporate Affairs & Business Opportunities Dr Rajen Manicka: rajen.m@holistaco.com General Enquiries: enquiries@holistaco.com
Media and Investor Relations: WeR1 Consultants Pte Ltd Karishma Ailsinghani E: holista@wer1.net; T: +65 84792656
About Holista CollTech Ltd
Holista CollTech Ltd ("Holista") is a research-driven biotech company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth and with extensive operations in Malaysia, the company is dedicated to delivering first-class natural ingredients and wellness products globally. Holista is a leader in the research of herbs and ingredients for the making of healthier food.
Listed on the Australian Securities Exchange ("ASX"), Holista researches, develops, manufactures and markets 'health-style' products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients, among other things, includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low calories sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.com
Source: Holista CollTech Ltd Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
MHI Delivers Final Trainset of Automated Guideway Transit System "2020 Series" to Saitama New Urban Transit Nov 28, 2024 10:08 JST
| TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market Nov 27, 2024 05:53 JST
| TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025 Nov 26, 2024 17:55 JST
| Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 15:50 JST
| Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues Nov 26, 2024 10:51 JST
| TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025 Nov 25, 2024 17:10 JST
| Toyota Submits Progress Report on Recurrence Prevention Measures Nov 25, 2024 15:43 JST
| TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market Nov 25, 2024 15:00 JST
| MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant Nov 25, 2024 14:18 JST
| Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship Nov 25, 2024 11:55 JST
| Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025 Nov 22, 2024 11:00 JST
| NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth Nov 21, 2024 22:59 JST
| Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan Nov 21, 2024 15:35 JST
| Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP Nov 21, 2024 09:00 JST
| ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study Nov 20, 2024 23:05 JST
| Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center Nov 20, 2024 15:30 JST
| Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan Nov 20, 2024 11:51 JST
| Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements Nov 20, 2024 10:24 JST
| Kingsoft Announces 2024 Third Quarter Results Nov 19, 2024 18:54 JST
| NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System Nov 19, 2024 15:30 JST
|
More Latest Release >>
|